Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Liver Diseases

• Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence.
• Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
• A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steat
• Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment
• Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
• Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
• Benefits of Trimetazidine in MAFLD Pateints
• ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial
• A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
• Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
• A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.
• Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
• Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)
• A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
• Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
• Dexamethasone/Pancreatic Clamp P&F
• The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
• Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH
• A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
• DZD9008 PK Study in Hepatic Impairment Subjects
• bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
• bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
• A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
• PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
• Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
• A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
• Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
• A Study of TAK-279 in Adults With or Without Liver Damage
• A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
• Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
• A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
• A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
• A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
• Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
• An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
• Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
• A Study About Fazirsiran in People With and Without Liver Problems
• A Clinical Study of Efinopegdutide in in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
• Vancomycin in Primary Sclerosing Cholangitis in Italy
• A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
• Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment
• Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients
• Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
• A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
• GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
• Semaglutide in Nonalcoholic Fatty Liver Disease
• Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）
• Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
• Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy
• Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
• Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
• Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
• SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
• Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
• Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
• A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men
• A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
• Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir
• Glycemic Effect of Diazoxide in NAFLD
• Pancreatic Clamp in NAFLD
• Different Regimens of Vitamin D in Treatment of Children With Chronic Liver Disease
• A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
• A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
• Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients
• Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
• A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
• REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. The RESUS Proof of Concept Study
• Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
• A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment
• Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease
• Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
• Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients
• A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
• Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
• N-acetyl Cysteine and Patients With Non-alcoholic Fatty Liver Disease
• Phase 2b Study of GSK4532990 in Adults With NASH
• A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.
• High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease
• A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Behaves in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function
• Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
• Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients
• Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
• Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
• Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
• First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease
• A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
• Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function
• Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
• Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
• Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants
• Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218
• A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
• Non-alcoholic Fatty Liver Disease and Its Treatment
• A Study to Investigate the Effects of Hepatic Impairment on the Pharmacokinetics of PF-07081532
• A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
• Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
• Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
• Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
• MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
• Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
• Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
• Alcohol, Gut Leakiness, & Liver Disease
• Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
• A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With No
• A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
• To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
• A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
• Fully Closed-Loop Insulin Delivery in Abdominal Surgery (CLAB)
• Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
• A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
• GATT-Patch Versus TachoSil in Liver Surgery
• A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
• The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study
• A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
• Quantifying Hepatic Mitochondrial Fluxes in Humans
• A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
• Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
• A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to th
• A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
• Growth Hormone in Decompensated Liver Cirrhosis
• Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
• Indocyanine Green Clearance Test in Liver Transplantation (LivInG)
• Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib
• Fruquintinib Hepatic Impairment Study
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
• An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
• TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
• A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
• A Phase 1 Study of NST-6179 in Healthy Subjects
• LGG Supplementation in Patients With AUD and ALD
• An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
• Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
• Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
• A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
• Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
• A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function
• Oral Docetaxel in Patients With Normal or Impaired Liver Function
• Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
• Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.
• Liraglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
• A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
• Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
• The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules
• Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex
• Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
• A Single and Repeat Dose Trial in Participants With Hepatic Impairment
• Alcoholic Liver Disease and the Gut Microbiome
• ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
• Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
• A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
• Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)
• Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment
• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
• An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
• A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
• A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
• A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
• Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
• Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
• Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
• A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
• The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
• Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
• Study in Healthy Adults Evaluating PF-07202954
• Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution
• A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
• A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
• Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes
• Vitamin E Dosing Study
• Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
• Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy
• Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
• A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
• Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
• Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
• Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
• Surufatinib Hepatic Impairment Study
• A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
• Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
• A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
• S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease
• FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
• Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease
• A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)
• Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
• Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
• Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.
• Combined Active Treatment in Type 2 Diabetes With NASH
• A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
• STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
• Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
• Angiotensin 2 for AKI After OLT
• Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment
• To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects
• Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
• Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK
• Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
• A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
• A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
• Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment
• A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
• Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
• Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function
• Effect of Midodrine on HVPG in Advanced Chronic Liver Disease
• Avatrombopag for Thrombocytopenia in People With Cancer
• The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects
• The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.
• The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
• Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
• A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With
• Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)
• A Study of JNJ-53718678 in Participants With Hepatic Impairment
• A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
• Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
• The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance
• Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
• Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment
• Acamprosate Safe to Use in Individuals With Liver Disease.
• Study of Single-dose DS-3201b in Participants With Hepatic Impairment
• Study to Evaluate the Pharmacokinetics (PK) of E7090 and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
• The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
• Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
• A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
• Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
• A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment
• Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379
• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989
• A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients
• An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NAS
• A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
• Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
• Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
• Study of DCR-A1AT in Healthy Adult Volunteers
• MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
• KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
• A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
• Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects
• Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment
• Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis
• Study on PK of Hydronidone in Patients and Special Population
• Curcumin for Pediatric Nonalcoholic Fatty Liver Disease
• Somatostatin in Living Donor Liver Transplantation
• Pirfenidone and Advanced Liver Fibrosis.
• Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
• The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
• A Multiple Ascending Dose Study of BIO89-100 in Subjects With Biopsy Confirmed NASH or NAFLD and at High Risk of NASH
• Vitamin D in Fatty Liver Disease
• Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
• Efficacy and Safety of Sodium Benzoate in the Management of Hyperammonemia in Infants, Children and Adolescent With Chronic Liver Disease.
• The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
• Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
• A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
• A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
• A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
• Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
• Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
• Study of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
• Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
• Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
• A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
• An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage
• Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
• SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
• Evaluate Severe Hepatic Impairment on Dacomitinib PK
• The Effect of Curcumin on Liver Fat Content in Obese Subjects
• Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
• Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
• Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease
• Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT
• A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers
• Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
• Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
• A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
• Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.
• Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects
• A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
• Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
• A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
• Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
• A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
• Hepatic Impairment Study for Lorlatinib in Cancer Patients
• A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
• Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
• A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
• Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
• An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
• PK Study in Subjects With Severe Hepatic Impairment
• A Renal Impairment Study for PF-04965842
• A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
• Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions
• Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
• Safety, Tolerability and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With NAFLD
• Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib
• A Hepatic Impairment Study for PF-04965842.
• Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
• MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
• Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
• The Effect and Safety of the Four Points Transversus Abdominis Plane Block
• A Study in Healthy Volunteers
• To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
• Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
• Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
• Study of Danicopan in Participants With Hepatic Impairment
• Tepotinib Hepatic Impairment Trial
• Hepatic Metabolic Changes in Response to Glucagon Infusion
• Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation
• Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
• Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction
• An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
• 2-Week Study In People With Nonalcoholic Fatty Liver Disease
• Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
• Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
• A Study of LY3314814 in Participants With Liver Impairment
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
• Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
• Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
• Losartan for the Treatment of Pediatric NAFLD
• Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
• A Study of Experimental Medication BMS-986036 Given to Healthy Participants
• Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
• Gemcabene for the Treatment of Pediatric NAFLD
• Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
• Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
• Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
• The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
• Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
• Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
• Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD
• Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
• A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
• A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
• Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis
• Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
• Paracetamol Metabolism Research in Postoperative Hepatic Surgery
• A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
• Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
• A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
• Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD)
• A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954
• 6-week Safety and PD Study in Adults With NAFLD
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
• Daprodustat Hepatic Impairment Study
• The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
• Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery
• DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
• Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
• Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment
• Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
• Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
• The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment
• Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment
• Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
• Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
• Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease.
• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
• A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
• Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
• Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding
• The Effects of Dexamethasone Administration on Jaundice Following Liver Resection
• A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
• Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
• Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
• Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis
• Silymarin in NAFLD
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
• A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
• Low-dose IL-2 for Treg Expansion and Tolerance (LITE)
• Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease
• Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.
• Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD
• deLIVER: Direct Acting Antiviral Effects on the Liver
• Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
• A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
• Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
• Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
• FDGal PET/CT to Detect Hepatocellular Carcinoma
• Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
• Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion
• Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
• A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
• A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
• A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
• Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease
• AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
• Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis
• A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
• Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
• Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
• Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
• Minocycline Administration During Human Liver Transplantation
• Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection
• SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
• PK Study of T-817 in Subjects With Hepatic Impairment
• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
• Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
• Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
• Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
• Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
• Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
• SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
• To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites
• Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery
• Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
• Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function
• Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.
• Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
• Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
• A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
• Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
• Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function
• Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation
• Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
• Tocotrienol Against the Progression of End Stage Liver Disease
• A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
• Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
• The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
• A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
• Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)
• Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
• Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease
• A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation
• A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
• Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
• Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients
• Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
• Compassionate Use of Omegaven IV Fat Emulsion
• INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
• Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
• PK Study of Sotagliflozin in Subjects With Hepatic Impairment
• Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
• Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
• Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
• Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
• Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease
• A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
• Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
• Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
• Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
• A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
• Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
• A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
• A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers
• To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease
• Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis
• RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
• ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
• The Effects of PXR Activation on Hepatic Fat Content
• Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
• Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
• Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
• Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
• Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment
• Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality
• Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM
• A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics
• A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
• The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease
• Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone
• A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
• A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
• A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
• Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
• Temocillin Pharmacokinetics in Paediatrics
• Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hep
• Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
• Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
• Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
• Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment
• Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment
• Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
• Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
• Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
• Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
• Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption
• Tesamorelin Effects on Liver Fat and Histology in HIV
• The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
• Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
• Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
• Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients
• Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
• Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
• Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
• A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
• PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
• Omegaven Expanded Access Protocol
• Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
• An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
• Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
• Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study
• Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
• A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
• To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
• Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis
• To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
• Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
• MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
• An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
• The INFECIR-2 Albumin Prevention Study
• Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
• Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
• Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
• Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
• Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury
• Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
• A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
• Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers
• Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
• A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
• Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
• EVP-6124 Hepatic Impairment Study
• Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
• Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
• Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
• Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
• Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
• Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
• Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus
• Effect of Hepatic Impairment on LDK378 Pharmacokinetics
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
• Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
• Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
• Antinociceptive Modalities on Ischemia Reperfusion Injury
• Risk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening
• Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
• Quantitative Liver Function Tests Using Cholates
• Hepatic Impairment Trial of Obeticholic Acid
• Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
• Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
• Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects
• The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease
• A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
• A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
• Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
• Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy
• Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
• Amlexanox for Type 2 Diabetes and Obesity
• Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC
• Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
• A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
• Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
• Myfortic in High MELD Liver Transplantation
• An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment
• A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
• Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
• Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment
• Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
• Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease
• Effects of Vitamin D on Inflammation in Liver Disease
• Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
• Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
• Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function
• Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment
• Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
• Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
• Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
• Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease
• Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
• Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
• Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease
• The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine
• Pasireotide LAR in Severe Polycystic Liver Disease
• Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
• Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
• Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
• A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
• Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis
• A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
• A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment
• Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
• Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
• A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
• A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers
• Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
• Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
• Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
• TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
• Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function
• Ursodeoxycholic Acid in Bariatric Surgery
• Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin
• S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)
• Pharmacokinetics of AGO178 in Participants With Liver Impairment
• Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers
• Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
• A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
• A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease
• Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
• Open-Label Hepatic Impairment Study
• Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
• Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
• Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
• Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation
• A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
• A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects
• Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
• Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
• Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects
• Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
• A PK and Safety Study in Subjects With Hepatic Impairment
• Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
• The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme
• PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
• Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury
• Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
• Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment
• Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects
• Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
• Use of N-Acetylcysteine During Liver Procurement
• Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease
• Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease
• Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)
• G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease
• Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)
• Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
• Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease
• A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
• Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
• Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
• Rifaximin in Fatty Liver Disease
• Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
• Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases
• Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis
• A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment
• Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
• Increlex Treatment of Children With Chronic Liver Disease and Short Stature
• Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
• Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib
• Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease
• Insulin Resistance in Non-alcoholic Fatty Liver Disease
• Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
• Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
• Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease
• The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
• A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
• A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
• Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
• A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.
• The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
• Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)
• GSK1349572 Hepatic Impairment Study
• A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function
• Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis
• Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
• Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)
• ¹³C-Methacetin Breath Test (MBT) Methodology Study
• Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
• Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
• Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
• Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease
• A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941
• A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
• Everolimus and LongActing Octreotide Trial in Polycystic Livers
• Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation
• Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
• Propofol and Remifentanyl Versus Midazolam and Fentanyl for Diagnostic Colonoscopy in Patients With Compensated Cirrhosis Child A-B
• Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease
• A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
• Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment
• Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment
• Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
• Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
• Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
• Fosamprenavir in Pts With Hepatic Impairment
• Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir
• Isoflurane Preconditioning for Liver Resections
• A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
• Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
• A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
• Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
• Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
• Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
• Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol
• University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
• Effect of Candesartan in Alcoholic Liver Fibrosis
• Propofol Versus Midazolam and Fentanyl for Diagnostic and Screening Colonoscopy in Patients With Advanced Liver Disease
• A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function
• A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function
• Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
• Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
• Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life
• Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
• Polycystic Liver Disease in Kidney Transplant
• Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
• Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
• Conditioning With Volatile Anesthetics in Liver Transplantation
• Cholestasis Reversal: Efficacy of IV Fish Oil
• Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
• Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics
• Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
• Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
• BG9928 in Subjects With Hepatic Impairment
• Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
• Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
• Hepatic Impairment Study
• Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
• Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
• Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
• Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects
• Study of Lactulose in Children With Chronic Liver Disease
• A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices
• Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
• Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
• A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
• Open-Label Extension of LOCKCYST Trial
• A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
• Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
• Colesevelam Versus Placebo in Cholestatic Pruritus
• Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
• Effect of Perioperative Sivelstat Administration for Liver Resection
• TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
• Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
• Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)
• Study of Fish Oil to Reduce ALT Levels in Adolescents
• Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
• A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
• Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment
• Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation
• Role of Exenatide in NASH-a Pilot Study
• Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -
• Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
• A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
• Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
• CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
• Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
• Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
• Effects of SAMe in Patients With Alcoholic Liver Disease
• Lanreotide as Treatment of Polycystic Livers
• A Study of Thymoglobulin and Tacrolimus in Liver Transplant
• Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery
• Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction
• Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
• Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
• Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
• Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
• YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation
• Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial
• Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
• Octreotide in Severe Polycystic Liver Disease
• Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function
• Phase I Trial of Silymarin for Chronic Liver Diseases
• A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
• A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment
• TachoSil Paediatric Liver Trial (TC-019-IN)
• Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
• Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment
• Metformin in Non-Alcoholic Fatty Liver Disease
• Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
• Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
• Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver
• Obesity and Nonalcoholic Fatty Liver Disease
• Insulin Resistance in Non-alcoholic Fatty Liver Disease
• Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
• Development of a Breath Test for Monitoring Patients With Liver Disease
• HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
• Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation
• Urotensin II and Vascular Tone in Cirrhosis
• Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
• Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
• A Phase II Study of DMP 115 to Assess Focal Liver Lesions
• Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
• Improving Hepatitis C Treatment in Injection Drug Users
• Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
• Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
• Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
• The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
• Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
• Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
• Gabapentin to Treat Itch in Patients With Liver Disease
• S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
• Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
• Total Parenteral Nutrition-Associated Liver Disease
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
• Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction
• Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction
• A Study of Zidovudine in HIV-Infected Patients With Liver Disease
• Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin